JGC
KROS icon

J. Goldman & Co’s Keros Therapeutics KROS Stock Holding History

J. Goldman & Co’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-40,000
Closed -$633K – 554
2024
Q4 		$633K Buy
+40,000
New +$2.08M 0.02% 357
2022
Q4 		– Sell
-54,000
Closed -$2.03M – 432
2022
Q3 		$2.03M Buy
+54,000
New +$1.87M 0.1% 206

Other funds holding KROS

N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

J. Goldman & Co's KROS Position: Q4 2024 in Review

J. Goldman & Co sold out of Keros Therapeutics (KROS) in Q4 2024, closing a stake of 54,236 shares — an estimated $2.82M sold.

J. Goldman & Co first reported a position in KROS in Q3 2022 and held it in 7 quarters. The position peaked at $3.15M in Q3 2024. 161 funds tracked by Wall St. Rank hold KROS as of Q4 2024.

  • J. Goldman & Co reported no remaining Keros Therapeutics position as of Q4 2024 after selling out during the quarter.
  • J. Goldman & Co sold 54,236 Keros Therapeutics shares in Q4 2024, an estimated $2.82M.
  • J. Goldman & Co first reported a position in Keros Therapeutics in Q3 2022 and held it in 7 quarters.
  • J. Goldman & Co's Keros Therapeutics position peaked at $3.15M in Q3 2024.
  • 161 funds tracked by Wall St. Rank held Keros Therapeutics as of Q4 2024.

Based on J. Goldman & Co's 13F filing for Q4 2024, filed 14 Feb 2025.